• Pablovski : Seems like no one does

  Report

  Reply
  Cancel Reply

• 74337002 : You got it wrong, it's BIIB and Eisai. Not bioa.

  Report

  Reply
  Cancel Reply

• 74337002 : Hope you get more sleep, carefully study the Stocks before trading

  Report

  Reply
  Cancel Reply

• Jaguar8 OP 74337002 : 01/13/2025 - 06:49 PM
  STOCKHOLM, Jan. 13, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Leqembi is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. The Prescription Drug User Fee Act (PDUFA) action date has been set to August 31, 2025.
  The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If LEQEMBI subcutaneous maintenance dosing is approved by the FDA, LEQEMBI will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector (AI). The injection process is expected to take, on average, 15 seconds. The SC-AI 360 mg weekly maintenance regimen will allow patients who have completed the biweekly intravenous (IV) initiation phase, exact period under discussion with the FDA, to receive weekly doses that are expected to maintain the clinical and biomarker benefits.
  The SC-AI is expected to be simple and easy for patients and their care partners to use, and may reduce the need for hospital or infusion site visits and nursing care for IV administration, which will make it easier to continue maintenance administration and may contribute to further simplifying the treatment pathway for AD.

  Report

  Reply
  Cancel Reply

• Jaguar8 OP 74337002 : I delivered the news which was released from BIOA. Eissa is not listed on Nasdaq nor NYSE Tell the BIOA that and not to me. I am not stupid.

  Report

  Reply
  Cancel Reply

• SJ24 : Based on my limited knowledge, pharma stocks tend to be very volatile. How do you manage that while also investing/trading in them?

  Report

  Reply
  Cancel Reply

View more comments...